BioArctic AB expands on its core focus of neurodegenerative disorders by maintaining a broad pipeline of preclinical and clinical-stage candidates. The company's flagship asset is lecanemab (marketed as Leqembi), an FDA-approved monoclonal antibody developed and commercialized globally in partnership with Eisai. Beyond Alzheimer's disease, BioArctic is developing treatments for Parkinson's disease and spinal cord injuries. A key component of its research is the proprietary BrainTransporter technology platform, designed to actively transport antibodies across the blood-brain barrier to enhance drug efficacy. The company operates a partnership-driven business model, discovering and developing medicines in-house before collaborating with larger pharmaceutical companies for late-stage clinical trials and global distribution. Consequently, BioArctic's revenue is primarily derived from research payments, milestone payments, and royalties tied to partner-led drug programs.
